Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$42.68 USD

42.68
1,202,042

-0.13 (-0.30%)

Updated May 2, 2024 04:00 PM ET

After-Market: $42.73 +0.05 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

QIAGEN's (QGEN) QCI Is Used by Danish National Genome Center

by Zacks Equity Research

QIAGEN's (QGEN) QCI Interpret offers evidence-based variant interpretation and reporting, and upholds the highest standards for data security and privacy. It also provides testing sites flexibility.

Qiagen (QGEN) Down 0.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN (QGEN) Expands Enzyme Offering to Aid Laboratory

by Zacks Equity Research

QIAGEN is a one-stop shop for all research needs, including solutions for sample preparation, automation and bioinformatics with enzyme offering expansion.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.

Qiagen (QGEN) Q1 Earnings Top Estimates, Operating Margin Down

by Zacks Equity Research

Amid an uncertain macroeconomic environment, Qiagen's (QGEN) first-quarter results reflect an impressive organic top line, led by strength in non-COVID-19 product groups.

Qiagen (QGEN) Q1 Earnings Beat Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 8.51% and 0.09%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Solid Biosciences Inc. (SLDB) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Solid Biosciences Inc. (SLDB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Qiagen (QGEN) Q1 Earnings Expected to Decline

by Zacks Equity Research

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers

by Zacks Equity Research

In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.

QIAGEN (QGEN) QIAxcel Connect Gets Red Dot Design Award

by Zacks Equity Research

QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 8.33% and 2.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact

by Zacks Equity Research

QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.

BD (BDX) Boosts Molecular Diagnostics Portfolio With New Tests

by Zacks Equity Research

Recent developments in the Molecular Diagnostics space have been aiding key MedTech players like BD (BDX) to boost their business.

QIAGEN's (QGEN) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

The ongoing double-digit sales growth in the non-COVID product portfolio contributed to QIAGEN's (QGEN) Q4 revenues.

Qiagen (QGEN) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Qiagen (QGEN) delivered earnings and revenue surprises of 12.77% and 3.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Qiagen (QGEN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

QIAGEN's (QGEN) New Launch to Enhance Clinical Lab Workflow

by Zacks Equity Research

QIAGEN's (QGEN) latest launch is expected to aid the clinical diagnostics labs to boost their performance.

QIAGEN (QGEN) Gains From Innovation, Currency Headwind Ails

by Zacks Equity Research

The QuantiFERON franchise is a key driver behind QIAGEN's (QGEN) molecular diagnostics growth.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN), led by progress in the test menu expansion strategy.

QIAGEN (QGEN) Acquires the Forensics NGS Firm Verogen

by Zacks Equity Research

QIAGEN's (QGEN) acquisition of Verogen fortifies the company's position in the fast-growing field of Human ID and forensics.

QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval

by Zacks Equity Research

QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.

QIAGEN's (QGEN) New Monkeypox Test to Aid Faster Identification

by Zacks Equity Research

QIAGEN's (QGEN) latest multiplex test is expected to strengthen its portfolio and boost its fight against the global monkeypox outbreak.

3 Reasons to Retain QIAGEN (QGEN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on the back of a series of product launches.